Evidence map›Paper›PMID 34332611›Full record

ArticleCancer cell international2021

Lnc-STYK1-2 regulates bladder cancer cell proliferation, migration, and invasion by targeting miR-146b-5p expression and AKT/STAT3/NF-kB signaling.

Ranran Dai, Qingping Jiang, You Zhou, Ruifeng Lin, Hai Lin, Yumin Zhang, Jinhu Zhang, Xingcheng Gao

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The role of PI3K/AKT signaling pathway in gallbladder carcinoma.American journal of translational research · 2022
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ranran Dai *Guangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.
Qingping Jiang *Department of Pathology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
You Zhou *Guangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.
Ruifeng LinGuangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.
Hai LinGuangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.
Yumin ZhangDepartment of Children's Stomatology, Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Jinhu ZhangGuangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.
Xingcheng GaoGuangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China. xchgao@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-0138-0805
Guangzhou Medical University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNStomatology Hospital · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

the Guangzhou Science and technology project 201904010037
6 · The paper itself

Abstract

backgroundEpigenetic modulation by noncoding RNAs substantially contributes to human cancer development, but noncoding RNAs involvement in bladder cancer remains poorly understood. This study investigated the role of long noncoding RNA (lncRNA) lnc-STYK1-2 in tumorigenesis in cancerous bladder cells.

methodsDifferential lncRNA and mRNA profiles were characterized by high-throughput RNA sequencing combined with validation via quantitative PCR. Bladder cancer cell proliferation was assessed through MTS, and bladder cancer cell migration and invasion were assessed through a Transwell system. The in vivo tumorigenesis of bladder cancer cells was evaluated using the cancer cell line-based xenograft model. The dual-luciferase reporter assay verified the association of miR-146b-5p with lnc-STYK1-2 and the target gene. Protein abundances and phosphorylation were detected by Western blotting.

resultsAlterations in lncRNA profiles, including decreased lnc-STYK1-2 expression, were detected in bladder cancer tissues compared with adjacent noncancerous tissues. lnc-STYK1-2 silencing effectively promoted proliferation, migration, and invasion in two bladder cancer cell lines, 5637 and T24, and their tumorigenesis in nude mice. lnc-STYK1-2 siRNA promoted miR-146b-5p and reduced ITGA2 expression in bladder cancer cells. Moreover, miR-146b-5p suppressed ITGA2 expression in bladder cancer cells through direct association. Also, lnc-STYK1-2 directly associated with miR-146b-5p. Finally, miR-146b-5p inhibitors abrogated the alterations in bladder cell functions, ITGA2 expression, and phosphorylation of AKT, STAT3, and P65 proteins in 5637 and T24 cells induced by lnc-STYK1-2 silencing.

conclusionlnc-STYK1-2 inhibited bladder cancer cell proliferation, migration, and tumorigenesis by targeting miR-146b-5p to regulate ITGA2 expression and AKT/STAT3/NF-kB signaling.

Indexed as

AKT/STAT3/NF-kBBladder cancerITGA2Lnc-STYK1-2Migration and invasionmiR-146b-5pProliferation

Identifiers

PMID34332611
PMCPMC8325849
OpenAlexW3189459957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.